CD14 and hepatocellular carcinoma: Previous studies [9, 15] defined TEMs as CD14+CD16+Tie2+ cells and reported that they were increased in HCC patients.TEMs are generally considered as a novel biomarker and potential therapeutic target for the diagnosis of HCC.